Consistent with primary tumor data, doublet LDM cyclophosphamide + MTD capecitabine increased HIF‐1α in liver metastases by 2.5‐ fold (P = 3.1 × 10−2; Fig 2B and Appendix Fig S4A), an induction that was blunted by doublet LDM cyclophosphamide+capecitabine (≈95% decrease, P = 8 × 10−4), equivalent to a reduction of ≈ 87% as compared to vehicle‐treated controls (P = 5.3 × 10−3; Fig 2B and Appendix Fig S4A). This evidence concerns the gene HIF1A and neoplasm.